These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26429709)

  • 1. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
    Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Waring JF; Yang J; Holen KD; Rosen LS
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1041-9. PubMed ID: 26429709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
    Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Kirschbrown W; Holen KD; Rosen LS
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1025-32. PubMed ID: 26420235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
    Cleary JM; Lima CM; Hurwitz HI; Montero AJ; Franklin C; Yang J; Graham A; Busman T; Mabry M; Holen K; Shapiro GI; Uronis H
    Invest New Drugs; 2014 Oct; 32(5):937-45. PubMed ID: 24916770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.
    Roberts AW; Advani RH; Kahl BS; Persky D; Sweetenham JW; Carney DA; Yang J; Busman TB; Enschede SH; Humerickhouse RA; Seymour JF
    Br J Haematol; 2015 Sep; 170(5):669-78. PubMed ID: 25942994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.
    Puglisi M; Molife LR; de Jonge MJ; Khan KH; Doorn LV; Forster MD; Blanco M; Gutierrez M; Franklin C; Busman T; Yang J; Eskens FA
    Future Oncol; 2021 Jul; 17(21):2747-2758. PubMed ID: 33849298
    [No Abstract]   [Full Text] [Related]  

  • 6. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.
    Fakih MG; Pendyala L; Smith PF; Creaven PJ; Reid ME; Badmaev V; Azrak RG; Prey JD; Lawrence D; Rustum YM
    Clin Cancer Res; 2006 Feb; 12(4):1237-44. PubMed ID: 16489079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
    Wilson WH; O'Connor OA; Czuczman MS; LaCasce AS; Gerecitano JF; Leonard JP; Tulpule A; Dunleavy K; Xiong H; Chiu YL; Cui Y; Busman T; Elmore SW; Rosenberg SH; Krivoshik AP; Enschede SH; Humerickhouse RA
    Lancet Oncol; 2010 Dec; 11(12):1149-59. PubMed ID: 21094089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
    Lewis NL; Scher R; Gallo JM; Engstrom PF; Szarka CE; Litwin S; Adams AL; Kilpatrick D; Brady D; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):257-65. PubMed ID: 12357298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
    Cohen SJ; Gallo J; Lewis NL; Alpaugh RK; Gentner L; Rogatko A; Yeslow G; Schol J; Verhaeghe T; Zannikos P; Palmer PA; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):513-8. PubMed ID: 14760509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer.
    Yang J; Pradhan RS; Rosen LS; Graham AM; Holen KD; Xiong H
    J Clin Pharm Ther; 2014 Dec; 39(6):680-4. PubMed ID: 25047139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors.
    Baz W; Nakhl F; El-Soueidi R; Forte F; Lowry J; Aoun N; Burton J
    Anticancer Drugs; 2009 Jul; 20(6):508-12. PubMed ID: 19318913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
    Ychou M; Raoul JL; Desseigne F; Borel C; Caroli-Bosc FX; Jacob JH; Seitz JF; Kramar A; Hua A; Lefebvre P; Couteau C; Merrouche Y
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):383-91. PubMed ID: 12439596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
    Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors.
    Chiang NJ; Chao TY; Hsieh RK; Wang CH; Wang YW; Yeh CG; Chen LT
    BMC Cancer; 2016 Nov; 16(1):907. PubMed ID: 27871319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
    Mross K; Steinbild S; Baas F; Gmehling D; Radtke M; Voliotis D; Brendel E; Christensen O; Unger C
    Eur J Cancer; 2007 Jan; 43(1):55-63. PubMed ID: 17095207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
    Couteau C; Risse ML; Ducreux M; Lefresne-Soulas F; Riva A; Lebecq A; Ruffié P; Rougier P; Lokiec F; Bruno R; Armand JP
    J Clin Oncol; 2000 Oct; 18(20):3545-52. PubMed ID: 11032597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
    Roberts AW; Seymour JF; Brown JR; Wierda WG; Kipps TJ; Khaw SL; Carney DA; He SZ; Huang DC; Xiong H; Cui Y; Busman TA; McKeegan EM; Krivoshik AP; Enschede SH; Humerickhouse R
    J Clin Oncol; 2012 Feb; 30(5):488-96. PubMed ID: 22184378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.
    Ishimoto O; Sugawara S; Inoue A; Maemondo M; Nukiwa T
    Respir Investig; 2015 Jul; 53(4):156-60. PubMed ID: 26100175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
    Veronese ML; Stevenson JP; Sun W; Redlinger M; Algazy K; Giantonio B; Hahn S; Vaughn D; Thorn C; Whitehead AS; Haller DG; O'Dwyer PJ
    Eur J Cancer; 2004 Mar; 40(4):508-14. PubMed ID: 14962716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
    Jimeno A; Rudek MA; Purcell T; Laheru DA; Messersmith WA; Dancey J; Carducci MA; Baker SD; Hidalgo M; Donehower RC
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):423-33. PubMed ID: 17429623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.